Nothing Special   »   [go: up one dir, main page]

CY1121763T1 - DIPYRAZOLE DERIVATIVES AS JAK INHIBITORS - Google Patents

DIPYRAZOLE DERIVATIVES AS JAK INHIBITORS

Info

Publication number
CY1121763T1
CY1121763T1 CY20191100510T CY191100510T CY1121763T1 CY 1121763 T1 CY1121763 T1 CY 1121763T1 CY 20191100510 T CY20191100510 T CY 20191100510T CY 191100510 T CY191100510 T CY 191100510T CY 1121763 T1 CY1121763 T1 CY 1121763T1
Authority
CY
Cyprus
Prior art keywords
dipyrazole
derivatives
jak inhibitors
jak
diseases
Prior art date
Application number
CY20191100510T
Other languages
Greek (el)
Inventor
Yun-Long Li
Jincong Zhuo
Ding-Quan Qian
Song MEI
Ganfeng Cao
Yongchun Pan
Qun Li
Zhongjiang JIA
Original Assignee
Incyte Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corporation filed Critical Incyte Corporation
Publication of CY1121763T1 publication Critical patent/CY1121763T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει ενώσεις του Τύπου I: ή φαρμακευτικώς αποδεκτά άλατα αυτών καθώς επίσης συνθέσεις αυτών και μεθόδους χρήσης αυτών που παρεμποδίζουν τη δραστικότητα κινάσης Janus (JAK) και είναι χρήσιμες στη θεραπεία ασθενειών που σχετίζονται προς τη δραστικότητα JAK που συμπεριλαμβάνουν, για παράδειγμα, φλεγμονώδεις διαταραχές, αυτοάνοσες διαταραχές, καρκίνο και άλλες ασθένειες.The present invention provides compounds of Formula I: or pharmaceutically acceptable salts thereof as well as compositions thereof and methods of using them that inhibit Janus kinase (JAK) activity and are useful in the treatment of diseases related to JAK activity including, for example, inflammatory disorders, autoimmune disorders, cancer and other diseases.

CY20191100510T 2013-05-17 2019-05-10 DIPYRAZOLE DERIVATIVES AS JAK INHIBITORS CY1121763T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361824683P 2013-05-17 2013-05-17
EP14732705.0A EP2997023B9 (en) 2013-05-17 2014-05-16 Bipyrazole derivatives as jak inhibitors
PCT/US2014/038388 WO2014186706A1 (en) 2013-05-17 2014-05-16 Bipyrazole derivatives as jak inhibitors

Publications (1)

Publication Number Publication Date
CY1121763T1 true CY1121763T1 (en) 2020-07-31

Family

ID=50983151

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20171100610T CY1119105T1 (en) 2013-05-17 2017-06-08 DIPYRAZOLI PRODUCTS AS JAK SUSPENSIONS
CY20191100510T CY1121763T1 (en) 2013-05-17 2019-05-10 DIPYRAZOLE DERIVATIVES AS JAK INHIBITORS
CY20211100050T CY1123756T1 (en) 2013-05-17 2021-01-22 DIPYRAZOLE DERIVATIVES AS JAK INHIBITORS

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20171100610T CY1119105T1 (en) 2013-05-17 2017-06-08 DIPYRAZOLI PRODUCTS AS JAK SUSPENSIONS

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20211100050T CY1123756T1 (en) 2013-05-17 2021-01-22 DIPYRAZOLE DERIVATIVES AS JAK INHIBITORS

Country Status (36)

Country Link
US (8) US9382231B2 (en)
EP (5) EP3231801B1 (en)
JP (5) JP6415543B2 (en)
KR (4) KR102729910B1 (en)
CN (2) CN105452239B (en)
AR (2) AR096330A1 (en)
AU (5) AU2014265279B2 (en)
BR (1) BR112015028501B8 (en)
CA (1) CA2911536C (en)
CL (1) CL2015003355A1 (en)
CR (2) CR20190156A (en)
CY (3) CY1119105T1 (en)
DK (3) DK3786162T3 (en)
EA (2) EA036448B1 (en)
ES (4) ES2626793T3 (en)
FI (1) FI3786162T3 (en)
HK (1) HK1245769B (en)
HR (4) HRP20170795T1 (en)
HU (4) HUE063817T2 (en)
IL (4) IL242453B (en)
LT (4) LT3231801T (en)
ME (2) ME03355B (en)
MX (2) MX385187B (en)
MY (1) MY174788A (en)
PE (2) PE20200527A1 (en)
PH (2) PH12015502563B1 (en)
PL (4) PL3786162T3 (en)
PT (4) PT3231801T (en)
RS (4) RS56012B1 (en)
SG (2) SG10201709469SA (en)
SI (4) SI2997023T1 (en)
SM (4) SMT202300352T1 (en)
TR (1) TR201905814T4 (en)
TW (3) TWI840646B (en)
UA (1) UA117830C2 (en)
WO (1) WO2014186706A1 (en)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006326548B2 (en) 2005-12-13 2012-04-05 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
SG10201912675VA (en) 2007-06-13 2020-02-27 Incyte Holdings Corp Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
BRPI1012108B8 (en) 2009-05-22 2021-05-25 Incyte Corp compound 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile, its composition, its uses and process for preparing a phosphoric acid salt
KR101771401B1 (en) 2009-05-22 2017-08-25 인사이트 홀딩스 코포레이션 N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
US8940752B2 (en) 2009-06-29 2015-01-27 Incyte Corporation Pyrimidinones as PI3K inhibitors
AR078012A1 (en) 2009-09-01 2011-10-05 Incyte Corp HETEROCICLIC DERIVATIVES OF PIRAZOL-4-IL-PIRROLO (2,3-D) PYRIMIDINS AS INHIBITORS OF THE QUANASA JANUS
PL3050882T3 (en) 2010-03-10 2018-08-31 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
HRP20160841T1 (en) 2010-05-21 2016-09-23 Incyte Holdings Corporation TOPICAL FORMULATION FOR A STRONG INHIBITOR
AU2011329734B2 (en) 2010-11-19 2015-05-28 Incyte Holdings Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
ES2764848T3 (en) 2010-12-20 2020-06-04 Incyte Holdings Corp N- (1- (substituted phenyl) ethyl) -9H-purine-6-amines as PI3K inhibitors
CN103797010B (en) 2011-06-20 2016-02-24 因塞特控股公司 As the azetidinyl phenyl of JAK inhibitor, pyridyl or pyrazinyl carboxamides derivatives
TW201313721A (en) 2011-08-18 2013-04-01 Incyte Corp Cyclohexyl azetidine derivatives as JAK inhibitors
SMT201900243T1 (en) 2011-09-02 2019-07-11 Incyte Holdings Corp Heterocyclylamines as pi3k inhibitors
UA111854C2 (en) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS
AR090548A1 (en) 2012-04-02 2014-11-19 Incyte Corp BICYCLIC AZAHETEROCICLOBENCILAMINS AS PI3K INHIBITORS
AR091079A1 (en) 2012-05-18 2014-12-30 Incyte Corp DERIVATIVES OF PIRROLOPIRIMIDINA AND PIRROLOPIRIDINA REPLACED WITH PIPERIDINILCICLOBUTILO AS JAK INHIBITORS
KR20150074193A (en) 2012-11-01 2015-07-01 인사이트 코포레이션 Tricyclic fused thiophene derivatives as jak inhibitors
EP3949953A1 (en) 2012-11-15 2022-02-09 Incyte Holdings Corporation Sustained-release dosage forms of ruxolitinib
PE20151902A1 (en) 2013-03-06 2015-12-26 Incyte Corp PROCESS AND INTERMEDIATES TO MAKE A JAK INHIBITOR
SI2997023T1 (en) * 2013-05-17 2017-07-31 Incyte Corporation Bipyrazole derivatives as jak inhibitors
PT3030227T (en) 2013-08-07 2020-06-25 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
EP3110409B1 (en) * 2014-02-28 2018-08-15 Incyte Corporation Jak1 inhibitors for the treatment of myelodysplastic syndromes
EP4501409A3 (en) 2014-04-08 2025-05-14 Incyte Holdings Corporation Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
TW201625643A (en) 2014-04-30 2016-07-16 英塞特公司 Processes of preparing a JAK1 inhibitor and new forms thereto
WO2015184305A1 (en) * 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US11382909B2 (en) 2014-09-05 2022-07-12 Sydnexis, Inc. Ophthalmic composition
US9586949B2 (en) 2015-02-09 2017-03-07 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
HUE053025T2 (en) 2015-02-27 2021-06-28 Incyte Corp Salts of pi3k inhibitor and processes for their preparation
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
HK1248570A1 (en) * 2015-05-29 2018-10-19 西德奈克西斯公司 D2o stabilized pharmaceutical formulations
SI3371190T1 (en) 2015-11-06 2022-08-31 Incyte Corporation Heterocyclic compounds as pi3k-gamma inhibitors
ES2833955T3 (en) 2016-01-05 2021-06-16 Incyte Corp Pyridines substituted with pyrazole / imidazole as PI3K-Gamma inhibitors
AR108875A1 (en) 2016-06-24 2018-10-03 Incyte Corp HETEROCYCLIC COMPOUNDS AS PI3K-g INHIBITORS
CN107759623B (en) * 2016-08-23 2020-08-14 苏州旺山旺水生物医药有限公司 Intermediates of JAK inhibitors and preparation methods thereof
MA46176A (en) * 2016-09-06 2019-07-17 Hoffmann La Roche 8- (AZETIDIN-1-YL) - [1,2,4] TRIAZOLO [1,5-A] PYRIDINYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
HRP20211827T1 (en) 2017-10-18 2022-03-18 Incyte Corporation Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
AR113922A1 (en) 2017-12-08 2020-07-01 Incyte Corp LOW DOSE COMBINATION THERAPY FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS
MA51771B1 (en) 2018-01-30 2022-03-31 Incyte Corp Processes for the preparation of (1-(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidin-4-one)
WO2019161098A1 (en) 2018-02-16 2019-08-22 Incyte Corporation Jak1 pathway inhibitors for the treatment of cytokine-related disorders
EP3773593B1 (en) 2018-03-30 2024-05-15 Incyte Corporation Treatment of hidradenitis suppurativa using jak inhibitors
US11584961B2 (en) 2018-03-30 2023-02-21 Incyte Corporation Biomarkers for inflammatory skin disease
EP3775923A1 (en) 2018-04-13 2021-02-17 Incyte Corporation Biomarkers for graft-versus-host disease
CN108484468A (en) * 2018-05-11 2018-09-04 南京大学 The preparation method of aryl azetidin compounds
MX2020012826A (en) 2018-06-01 2021-03-09 Incyte Corp DOSAGE REGIMEN FOR THE TREATMENT OF DISORDERS RELATED TO PHOSPHATIDYLINOSITOL 3-KINASES (PI3K).
CR20250050A (en) 2018-09-05 2025-03-19 Incyte Corp Crystalline forms of a phosphoinositide 3-kinase (pi3k) inhibitor
CN113490484B (en) 2018-10-31 2024-08-23 因赛特公司 Combination therapy for treating hematological disorders
MA54544A (en) 2018-12-19 2021-10-27 Incyte Corp JAK1 PATHWAY INHIBITORS FOR THE TREATMENT OF GASTROINTESTINAL DISEASE
KR20210137087A (en) 2019-03-05 2021-11-17 인사이트 코포레이션 JAK1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
US11624751B2 (en) 2019-03-19 2023-04-11 Incyte Corporation Biomarkers for vitiligo
KR20210142154A (en) 2019-03-21 2021-11-24 옹쎄오 DBAIT molecules in combination with kinase inhibitors for the treatment of cancer
US20210123931A1 (en) 2019-10-10 2021-04-29 Incyte Corporation Biomarkers for graft-versus-host disease
US12203942B2 (en) 2019-10-10 2025-01-21 Incyte Corporation Biomarkers for graft-versus-host disease
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
JP7518900B2 (en) * 2019-10-16 2024-07-18 インサイト・コーポレイション Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (LP) - Patent Application 20070233334
AU2020378630A1 (en) 2019-11-08 2022-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
SMT202400509T1 (en) * 2020-06-02 2025-01-14 Incyte Corp PROCEDURES FOR PREPARING A JAK1 INHIBITOR
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2022040180A1 (en) 2020-08-18 2022-02-24 Incyte Corporation Process and intermediates for preparing a jak inhibitor
MX2023002035A (en) 2020-08-18 2023-06-12 Incyte Corp Process and intermediates for preparing a jak1 inhibitor.
CN112159394B (en) * 2020-10-09 2021-10-22 嘉兴特科罗生物科技有限公司 A small molecule compound as JAK kinase inhibitor and its use
PT4255442T (en) 2020-12-04 2025-05-19 Incyte Corp Jak inhibitor with a vitamin d analog for treatment of skin diseases
CA3204374A1 (en) 2020-12-08 2022-06-16 Incyte Corporation Jak1 pathway inhibitors for the treatment of vitiligo
CN114099514A (en) * 2020-12-29 2022-03-01 上海岸阔医药科技有限公司 Methods for preventing or treating side effects associated with EGFR dysfunction
US11918581B2 (en) 2021-01-11 2024-03-05 Incyte Corporation Combination therapy comprising JAK pathway inhibitor and rock inhibitor
KR20240009964A (en) 2021-05-03 2024-01-23 인사이트 코포레이션 JAK1 pathway inhibitors for the treatment of prurigo nodosum
CN118317946A (en) 2021-07-12 2024-07-09 因赛特公司 Processes and intermediates for the preparation of baratinib
TW202419088A (en) 2022-08-05 2024-05-16 美商英塞特公司 Treatment of urticaria using jak inhibitors
WO2024192350A1 (en) 2023-03-16 2024-09-19 Incyte Corporation Jak1 pathway inhibitors for the treatment of asthma
CN117186078A (en) * 2023-11-06 2023-12-08 药康众拓(北京)医药科技有限公司 Deuterated azetidine JAK inhibitor medicine and application thereof

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60106847U (en) 1983-12-27 1985-07-20 富士重工業株式会社 outdoor rear view mirror
JP2650681B2 (en) 1987-07-10 1997-09-03 株式会社ブリヂストン Air spring
JPH0515775Y2 (en) 1987-07-13 1993-04-26
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
CN1152031C (en) 1998-08-11 2004-06-02 诺瓦提斯公司 Isoquinoline derivatives with angiogenesis inhibiting activity
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
ES2225624T3 (en) 2000-06-28 2005-03-16 Smithkline Beecham Plc GRINDING PROCEDURE BY WET.
WO2003024967A2 (en) 2001-09-19 2003-03-27 Aventis Pharma S.A. Indolizines as kinase protein inhibitors
JP4959918B2 (en) 2001-10-30 2012-06-27 ノバルティス アーゲー Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity
PE20040522A1 (en) 2002-05-29 2004-09-28 Novartis Ag DIARYLUREA DERIVATIVES DEPENDENT ON PROTEIN KINASE
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
CL2003002353A1 (en) 2002-11-15 2005-02-04 Vertex Pharma COMPOUNDS DERIVED FROM DIAMINOTRIAZOLS, INHIBITORS D ELA PROTEINA QUINASA; PHARMACEUTICAL COMPOSITION; PREPARATION PROCEDURE; AND ITS USE OF THE COMPOUND IN THE TREATMENT OF DISEASES OF ALLERGIC DISORDERS, PROLIFERATION, AUTOIMMUNES, CONDIC
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
PE20050952A1 (en) 2003-09-24 2005-12-19 Novartis Ag DERIVATIVES OF ISOQUINOLINE AS INHIBITORS OF B-RAF
EP1885352A2 (en) 2004-11-24 2008-02-13 Novartis AG Combinations comprising jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors
AU2006326548B2 (en) 2005-12-13 2012-04-05 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
CL2008001709A1 (en) 2007-06-13 2008-11-03 Incyte Corp Compounds derived from pyrrolo [2,3-b] pyrimidine, jak kinase modulators; pharmaceutical composition; and use in the treatment of diseases such as cancer, psoriasis, rheumatoid arthritis, among others.
SG10201912675VA (en) 2007-06-13 2020-02-27 Incyte Holdings Corp Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
BRPI0820544A2 (en) * 2007-11-16 2015-06-16 Incyte Corp 4-pyrazolyl-n-arylpyrimidin-2-amines and pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
HUE029767T2 (en) * 2008-03-11 2017-04-28 Incyte Holdings Corp Azetidine and cyclobutane derivatives as jak inhibitors
CL2009001884A1 (en) 2008-10-02 2010-05-14 Incyte Holdings Corp Use of 3-cyclopentyl-3- [4- (7h-pyrrolo [2,3-d] pyrimidin-4-yl) -1h-pyrazol-1-yl) propanonitrile, janus kinase inhibitor, and use of a composition that understands it for the treatment of dry eye.
JOP20190231A1 (en) 2009-01-15 2017-06-16 Incyte Corp Processes for preparing jak inhibitors and related intermediate compounds
KR101771401B1 (en) 2009-05-22 2017-08-25 인사이트 홀딩스 코포레이션 N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
BRPI1012108B8 (en) 2009-05-22 2021-05-25 Incyte Corp compound 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile, its composition, its uses and process for preparing a phosphoric acid salt
AR078012A1 (en) 2009-09-01 2011-10-05 Incyte Corp HETEROCICLIC DERIVATIVES OF PIRAZOL-4-IL-PIRROLO (2,3-D) PYRIMIDINS AS INHIBITORS OF THE QUANASA JANUS
BR112012008267B1 (en) 2009-10-09 2022-10-04 Incyte Holdings Corporation 3-(4-(7H-PYROLO[2,3-D]PYRIMIDIN-4-IL)-1H-PYRAZOL-1-IL)-3-CYCLOPENTYLPROPANONITRILE 3-(4-(7H-PYROXYL, KETO, AND GLUCURONIDE) DERIVATIVES
AU2011217961B2 (en) 2010-02-18 2016-05-05 Incyte Holdings Corporation Cyclobutane and methylcyclobutane derivatives as Janus kinase inhibitors
PL3050882T3 (en) 2010-03-10 2018-08-31 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
SG184870A1 (en) * 2010-04-14 2012-11-29 Array Biopharma Inc 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases
HRP20160841T1 (en) 2010-05-21 2016-09-23 Incyte Holdings Corporation TOPICAL FORMULATION FOR A STRONG INHIBITOR
AU2011329734B2 (en) 2010-11-19 2015-05-28 Incyte Holdings Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
EP2640725B1 (en) 2010-11-19 2015-01-07 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
CA2820109C (en) 2010-12-10 2018-01-09 Rottapharm S.P.A. Pyridine amide derivatives as ep4 receptor antagonists
SG192910A1 (en) 2011-02-24 2013-09-30 Massachusetts Inst Technology ALTERNATIVELY SPLICED mRNA ISOFORMS AS PROGNOSTIC INDICATORS FOR METASTATIC CANCER
CN103797010B (en) 2011-06-20 2016-02-24 因塞特控股公司 As the azetidinyl phenyl of JAK inhibitor, pyridyl or pyrazinyl carboxamides derivatives
TW201313721A (en) 2011-08-18 2013-04-01 Incyte Corp Cyclohexyl azetidine derivatives as JAK inhibitors
UA111854C2 (en) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS
AU2012313094B2 (en) 2011-09-22 2017-02-02 Intervet International B.V. Pyrazole carboxamides as janus kinase inhibitors
AR091079A1 (en) * 2012-05-18 2014-12-30 Incyte Corp DERIVATIVES OF PIRROLOPIRIMIDINA AND PIRROLOPIRIDINA REPLACED WITH PIPERIDINILCICLOBUTILO AS JAK INHIBITORS
KR20150074193A (en) 2012-11-01 2015-07-01 인사이트 코포레이션 Tricyclic fused thiophene derivatives as jak inhibitors
EP3949953A1 (en) 2012-11-15 2022-02-09 Incyte Holdings Corporation Sustained-release dosage forms of ruxolitinib
PE20151902A1 (en) 2013-03-06 2015-12-26 Incyte Corp PROCESS AND INTERMEDIATES TO MAKE A JAK INHIBITOR
US9266904B2 (en) 2013-05-17 2016-02-23 Hoffmann-La Roche Inc. 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection
SI2997023T1 (en) 2013-05-17 2017-07-31 Incyte Corporation Bipyrazole derivatives as jak inhibitors
JO3603B1 (en) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc Sulfamoyl pyrolamide derivatives and their use as medicines to treat hepatitis B
US9371282B2 (en) 2013-05-17 2016-06-21 Centrexion Therapeutics Corporation Somatostatin receptor subtype 4 (SSTR4) agonists
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
PT3030227T (en) 2013-08-07 2020-06-25 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
EP3110409B1 (en) 2014-02-28 2018-08-15 Incyte Corporation Jak1 inhibitors for the treatment of myelodysplastic syndromes
TW201625643A (en) 2014-04-30 2016-07-16 英塞特公司 Processes of preparing a JAK1 inhibitor and new forms thereto
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
SG11201704053WA (en) 2014-12-16 2017-06-29 Novartis Ag Isoxazole hydroxamic acid compounds as lpxc inhibitors
WO2019161098A1 (en) 2018-02-16 2019-08-22 Incyte Corporation Jak1 pathway inhibitors for the treatment of cytokine-related disorders
SMT202400509T1 (en) 2020-06-02 2025-01-14 Incyte Corp PROCEDURES FOR PREPARING A JAK1 INHIBITOR
PT4255442T (en) 2020-12-04 2025-05-19 Incyte Corp Jak inhibitor with a vitamin d analog for treatment of skin diseases
CA3204374A1 (en) 2020-12-08 2022-06-16 Incyte Corporation Jak1 pathway inhibitors for the treatment of vitiligo

Also Published As

Publication number Publication date
FI3786162T3 (en) 2023-10-02
LT3786162T (en) 2023-11-27
PL3231801T3 (en) 2019-07-31
EA036448B1 (en) 2020-11-11
SG11201509180WA (en) 2015-12-30
PH12015502563B1 (en) 2019-04-26
US9382231B2 (en) 2016-07-05
DK3231801T3 (en) 2019-04-15
SG10201709469SA (en) 2017-12-28
AR118120A2 (en) 2021-09-22
KR20220127371A (en) 2022-09-19
NZ753637A (en) 2020-11-27
US20140343030A1 (en) 2014-11-20
WO2014186706A1 (en) 2014-11-20
JP2022163162A (en) 2022-10-25
JP7126741B2 (en) 2022-08-29
AU2020202000A1 (en) 2020-04-09
NZ753638A (en) 2020-11-27
US9926301B2 (en) 2018-03-27
EP2997023A1 (en) 2016-03-23
DK3786162T3 (en) 2023-10-09
PH12015502563A1 (en) 2016-02-22
US20180312492A1 (en) 2018-11-01
IL264409A (en) 2019-02-28
RS58743B1 (en) 2019-06-28
TWI719401B (en) 2021-02-21
IL287313B (en) 2022-03-01
BR112015028501B8 (en) 2023-01-24
ES2626793T3 (en) 2017-07-26
SI3231801T1 (en) 2019-05-31
RS64591B1 (en) 2023-10-31
SMT201700258T1 (en) 2017-07-18
NZ713999A (en) 2020-11-27
CA2911536A1 (en) 2014-11-20
AU2018223058A1 (en) 2018-09-20
US11001571B2 (en) 2021-05-11
PH12018502125A1 (en) 2019-03-25
SMT201900223T1 (en) 2019-07-11
KR102442747B1 (en) 2022-09-14
ME02763B (en) 2018-01-20
US10435392B2 (en) 2019-10-08
CA2911536C (en) 2021-07-20
CN105452239A (en) 2016-03-30
AU2020202000B2 (en) 2021-03-11
MX373238B (en) 2020-05-08
IL282644A (en) 2021-06-30
PL2997023T3 (en) 2017-08-31
HUE033587T2 (en) 2017-12-28
HUE043573T2 (en) 2019-08-28
EP3231801A1 (en) 2017-10-18
JP2024105557A (en) 2024-08-06
JP2021008493A (en) 2021-01-28
NZ753639A (en) 2020-11-27
IL287313A (en) 2021-12-01
SI2997023T1 (en) 2017-07-31
CN107698569A (en) 2018-02-16
MX385187B (en) 2025-03-14
AU2014265279B2 (en) 2018-09-27
KR20240063187A (en) 2024-05-10
US11905275B2 (en) 2024-02-20
AU2022263454B2 (en) 2024-01-18
SMT202100040T1 (en) 2021-03-15
HUE063817T2 (en) 2024-01-28
JP2019011364A (en) 2019-01-24
EP3786162B1 (en) 2023-08-09
US20250206726A1 (en) 2025-06-26
IL242453B (en) 2019-11-28
EP2997023B1 (en) 2017-03-22
TW201940479A (en) 2019-10-16
CR20150633A (en) 2016-04-05
ME03355B (en) 2019-10-20
EP2997023B9 (en) 2018-06-13
CL2015003355A1 (en) 2016-05-27
US11591318B2 (en) 2023-02-28
CY1123756T1 (en) 2022-05-27
JP2016519147A (en) 2016-06-30
AU2021202685A1 (en) 2021-05-27
KR102663357B1 (en) 2024-05-14
HK1245769B (en) 2020-02-07
ES2845210T3 (en) 2021-07-26
AU2021202685B2 (en) 2022-11-17
PT2997023T (en) 2017-05-31
HRP20170795T1 (en) 2017-08-25
RS61482B1 (en) 2021-03-31
TWI664176B (en) 2019-07-01
JP6415543B2 (en) 2018-10-31
US20210238168A1 (en) 2021-08-05
KR20210120120A (en) 2021-10-06
IL264409B (en) 2021-05-31
BR112015028501B1 (en) 2022-11-01
AU2022263454A1 (en) 2022-12-08
NZ753636A (en) 2020-11-27
EP4275756A3 (en) 2024-02-07
US20240150327A1 (en) 2024-05-09
BR112015028501A2 (en) 2017-07-25
EP3527263A1 (en) 2019-08-21
UA117830C2 (en) 2018-10-10
PL3786162T3 (en) 2024-04-08
CR20190156A (en) 2019-05-16
AU2014265279A1 (en) 2015-11-26
HUE053122T2 (en) 2021-06-28
ES2720073T3 (en) 2019-07-17
EA202090291A3 (en) 2020-06-30
CN105452239B (en) 2017-11-21
IL282644B (en) 2021-10-31
TW202116320A (en) 2021-05-01
RS56012B1 (en) 2017-09-29
MX2020004506A (en) 2021-08-09
CN107698569B (en) 2020-11-27
MY174788A (en) 2020-05-14
PL3527263T3 (en) 2021-05-17
HK1221466A1 (en) 2017-06-02
TW201512191A (en) 2015-04-01
US20160289215A1 (en) 2016-10-06
EP4275756A2 (en) 2023-11-15
SMT202300352T1 (en) 2024-01-10
EP3527263B1 (en) 2020-10-28
PT3527263T (en) 2021-02-01
PT3786162T (en) 2023-10-20
TW202432140A (en) 2024-08-16
JP6775560B2 (en) 2020-10-28
HRP20210119T1 (en) 2021-03-05
US12247020B2 (en) 2025-03-11
TR201905814T4 (en) 2019-05-21
SI3527263T1 (en) 2021-05-31
KR102341908B1 (en) 2021-12-23
TWI840646B (en) 2024-05-01
US20230159501A1 (en) 2023-05-25
EA039660B1 (en) 2022-02-24
ES2960731T3 (en) 2024-03-06
PE20200527A1 (en) 2020-03-09
EP3786162A1 (en) 2021-03-03
KR102729910B1 (en) 2024-11-15
PE20160126A1 (en) 2016-02-24
LT3231801T (en) 2019-08-12
LT2997023T (en) 2017-06-26
EP3231801B1 (en) 2019-02-13
DK3527263T3 (en) 2021-01-25
EA202090291A2 (en) 2020-05-31
AR096330A1 (en) 2015-12-23
MX2015015738A (en) 2016-03-16
PT3231801T (en) 2019-05-24
US20200010456A1 (en) 2020-01-09
KR20160019905A (en) 2016-02-22
CY1119105T1 (en) 2018-02-14
LT3527263T (en) 2021-05-10
HRP20190713T1 (en) 2019-06-14
SI3786162T1 (en) 2024-02-29
AU2018223058B2 (en) 2020-01-02
HRP20231048T1 (en) 2023-12-22
EA201592199A1 (en) 2016-05-31

Similar Documents

Publication Publication Date Title
CY1123756T1 (en) DIPYRAZOLE DERIVATIVES AS JAK INHIBITORS
CY1122601T1 (en) GSK3 INHIBITORS AND METHODS OF USING THEREOF
CY1120866T1 (en) DNA-PK INHIBITORS
CY1123388T1 (en) NICOTINIMIDE SUBSTITUTED BTK INHIBITORS AND THEIR PREPARATION AND USE IN THE TREATMENT OF CANCER, INFLAMMATION AND AUTOIMMUNE DISEASE
CY1122712T1 (en) USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kδ RELATED DISORDERS
CY1121413T1 (en) DIHYDROPYRROLOPYRIDINE ROR-GAMMA INHIBITORS
CY1120154T1 (en) Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
CY1120104T1 (en) Suspensions of SYK
EA201690752A1 (en) INHIBITORS G12C KRAS
EA201891229A1 (en) EIF4A-INHIBITING COMPOUNDS AND RELATED METHODS
JOP20190174B1 (en) Selective JAK1 inhibitors
MD4800B1 (en) Aminopyrimidinyl compounds as JAK inhibitors
MX377916B (en) 4-AMINO-IMIDAZOQUINOLINE COMPOUNDS.
EA201490042A1 (en) AZETIDINYL-PHENYL-, PYRIDYL- OR PYRAZYNYLKARBOXAMID DERIVATIVES AS INHIBITORS
MX382991B (en) ARGININE METHYLTRANSFERASE INHIBITORS AND THEIR USES.
EA201690094A1 (en) SYK INHIBITORS
EA201591753A1 (en) 3-PYRIMIDIN-4-ILOXAZOLIDIN-2-ONE AS MUTANT IDH INHIBITORS
EA201690268A1 (en) SUBSTITUTED HINAZOLIN-4-SHE DERIVATIVES
EA201891063A1 (en) DERIVATIVES OF DIHYDROIMIDAZOPIRAZINONE APPLICABLE IN THE TREATMENT OF CANCER
EA201591360A1 (en) AZABENZIMADAZLES AS INHIBITORS INHIBITORS PDE4 FOR THE TREATMENT OF THE CNS AND OTHER DISORDERS
EA201600434A1 (en) APPLICATION OF DERIVATIVES OF BENZIMIDAZOLPROLINE
EA201790830A1 (en) ALDOSTERONSYNTASE INHIBITORS
CY1120608T1 (en) PHARMACEUTICAL ACTIVE COMPOUNDS
EA201650003A1 (en) CYCLOALCYL-DIGETERO-CYCLIC DERIVATIVES
EA201600002A1 (en) DERIVATIVES OF SUBSTITUTED TRIAZOLOPIRIDINES